Perthera

About Perthera

Established in 2012, Perthera operates as a therapeutic intelligence company focused on advancing precision medicine in oncology. The company was co-founded by Dendy Young and Emanuel “Chip” Petricoin, PhD, who serves as the Chief Science Officer. Dr. Petricoin, a professor at George Mason University and co-director of the Center for Applied Proteomics and Molecular Medicine, brought together a team of experts in oncology, bioinformatics, and scientific research to create a solution that integrates complex data to inform cancer treatment. This initiative was born from the understanding that genomic testing alone provides an incomplete picture of a patient's cancer.

Perthera's business model centers on its proprietary, AI-driven Precision Oncology Platform. The company serves multiple client types, including oncologists, hospitals, clinical research organizations (CROs), and biopharmaceutical companies. For clinical clients, Perthera generates revenue by providing decision support services. Its platform analyzes a patient's comprehensive medical and treatment history alongside multi-omic molecular data (genomics, proteomics, etc.) from any testing source to generate the Perthera Report®. This report provides a ranked list of therapeutic options, including FDA-approved drugs and potential clinical trials, tailored to the patient's specific cancer profile. The service is augmented by a virtual Molecular Tumor Board, which offers expert review for each case. For biopharma clients, Perthera offers access to its curated real-world evidence (RWE) data pipeline to accelerate drug development, support regulatory submissions, and improve clinical trial matchmaking.

The core of Perthera's offering is its Therapeutic Intelligence Engine, which utilizes over 80,000 heuristic rules and algorithms to synthesize vast amounts of data. This engine powers the Perthera Report®, a detailed analysis that simplifies complex molecular information into actionable treatment recommendations for oncologists. By creating a feedback loop where real-world patient outcomes are recorded and used to refine future recommendations, the platform continuously enhances its predictive capabilities. The company has formed strategic partnerships with organizations like the Colorectal Cancer Alliance and biopharma companies to expand patient access, facilitate clinical trial enrollment, and accelerate research. Having raised approximately $26.8M in funding, Perthera is backed by investors including Pilot Growth Equity and Invictus Growth.